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osting by EAbstract Hypersensitive reactions to eyedrops are a common ﬁnding in clinical practice and rep-
resent a frequent cause of discontinuation of the therapy. Moreover, experimental and clinical stud-
ies show that long term use of topical drugs may induce ocular surface changes causing discomfort
and potentially negatively affecting the compliance to the treatment as well as the success rate of
ﬁltering procedures. The exact mechanism involved and the roles of the active compound and
the preservatives in inducing such detrimental effects of ophthalmic solutions are unclear. During
the last years several antiglaucoma agents have been marketed as either preservative-free or ben-
zalkonium chloride-free formulations in an attempt to reduce the adverse effects related to preser-
vatives. This paper summarizes the body of evidence from existing studies about preservatives in
antiglaucoma eyedrops, focusing on the latest compounds commercially available. A systematic
review of the literature was performed.
Current research is focusing not only on the efﬁcacy of the drugs but also on their tolerability.
Based on the existing data, there is a rationale to support the use of benzalkonium-free solutions
whenever possible, especially in patients suffering from concomitant ocular surface diseases, expe-
riencing local side effects and in those expected to need multiple and prolonged topical treatments.
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Glaucoma is a group of ocular diseases with multifactorial
aetiology characterized by a clinically characteristic optic neu-
ropathy and associated visual ﬁeld loss (Falkenberg and Bex,
2007). The vast majority of glaucomatous patients are older
than 60 years, and due to longer life expectancy, the prevalence
of glaucoma is increasing worldwide (Coleman, 1999).
The relative risk to develop glaucoma rises continuously
with the level of the intra-ocular pressure (IOP); however,
there is no evidence of a threshold IOP for the onset of the dis-
ease (European Glaucoma Society, 2008a).
Primary open-angle glaucoma (POAG), the most common
form of the disease in the western world, can be categorized as
either ‘‘high pressure’’ or ‘‘normal pressure’’, depending
whether the IOP lies above or under the normally expected
range, In both cases, there is a characteristic cupping of the
optic disc along with possible visual ﬁeld loss and loss of reti-
nal ganglion cells. If the IOP is consistently more than two
standard deviations above the normal mean, while all other
ocular ﬁndings (visual ﬁeld, optic disc appearance etc.) are
within normal limits, the condition is classiﬁed as ocular
hypertension (OH). Exfoliation syndrome and pigment disper-
sion are risk factors for secondary open-angle glaucoma. Trau-
ma, or conditions such as uveitis, may cause damage to the
drainage pathways within the eye, and, therefore, be linked
to the onset of secondary open-angle glaucoma (Yee, 2007).
Angle-closure glaucoma (AGC), is caused by forces which
either pull (e.g., neovascularization of the iris, inﬂammation)
or push (pupillary block, posterior synechiae, uveitis) the iris
forward or push the lens forward (e.g., mature cataract, small
anterior segment) thereby narrowing the iridocorneal angle. In
its primary form, angle closure is more frequent in Asian
population.
Although many molecules aimed to arrest or even reverse
the apoptotic damage of the optic nerve and retinal ganglion
cells (Ammar et al., 2011), elevated IOP is still considered
the most important risk factor for glaucoma development.
At present, the only effective treatment for glaucoma is to low-
er the IOP and for this purpose a broad spectrum of medica-
tions are available (Leske et al., 2008).
IOP can be lowered either through a decrease of aqueous
production (i.e., the amount of aqueous that is produced by
the ciliary tissues), or by increasing outﬂow through the conven-
tional trabecular pathway or the alternate uveoscleral pathway.Many of the currently available topical medications are
associated with adverse effects, such as dry eye, burning, sting-
ing sensations, tearing and allergic reactions (Jaenen et al.,
2007). Discomfort due to instillation, or ocular adverse events
caused by the drug itself, may have an impact on the patient’s
quality of life, and are thought to be associated with poor
compliance. This leads to poor IOP control, which in turn,
may increase the need for eventual ﬁltration surgery, which
is associated with risks, the most common being an increase
cataract formation (Baudouin, 2008).
2. Antiglaucoma drugs and therapeutic regimens
The goal of glaucoma treatment is to maintain the patient’s
visual function and related quality of life (European Glaucoma
Society, 2008b). Besides the functional loss and having the
diagnosis of a potentially blinding disease, other factors alone
or in combination may affect patients’ quality of life: inconve-
nience of the treatment, side effects and therapy costs.
Most patients with POAG are initially treated with topical
medications. Ideally one should use the lowest dose of a partic-
ular drug that will produce the greatest therapeutic response
with the least number of side effects. Indeed, many of the
currently available topical medications are associated with
adverse effects, such as dry eye, burning, stinging sensations,
tearing and allergic reactions (Jaenen et al., 2007). There is a
general consensus to start glaucoma medical therapy with
one topical intraocular pressure (IOP) lowering medication.
If the ﬁrst choice monotherapy alone is not effective to reduce
IOP or is not tolerated, it is preferable to switch to another
molecule that is initiated as monotherapy. Adjunctive therapy
should be considered whenever a monotherapy does not reach
target IOP or the target must be lowered as the disease is pro-
gressing (South East Asia Glaucoma Interest Group, 2008;
European Glaucoma Society, 2008c). Antiglaucoma drugs
can be combined with each other in order to reach the target
IOP. As a general rule, in most patients it is not recommended
to use more than two drugs in two separate bottles or to add
more than one single drug to a ﬁxed-combination since compli-
ance is likely to suffer. However, multiple topical treatments
are often required to reduce the IOP to the desirable target.
Glaucomatous patients have been shown to suffer from
symptoms related to ocular surface disease (i.e., burning, itch-
ing, red eye, tearing, blurred vision) in a higher prevalence than
normal population (Stewart et al., 2011). Although the cause is
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cations seems to play a major role and the prevalence appears
to increase with the greater the number of antiglaucoma drops
prescribed (Stewart et al., 2011). Long-term use of topical
drugs, especially in those patients receiving a multiple drop
regimen, may be detrimental as a dose- and time-dependent
consequence to benzalkonium chloride exposure (Serle et al.,
2004) There is now increasing evidence to demonstrate that a
sizable portion of local side effects may result from the preser-
vatives rather than from the active compounds. There may be
a direct correlation between the presence of preservatives and
the surface symptoms provoked by anti-glaucoma therapy
(Serle et al., 2004); reducing such exposure could improve
the patient’s comfort and thus his compliance.
3. Antiglaucoma drugs and allergic reactions
Topical IOP-lowering drugs can cause different reactions on
ocular structures, especially on the ocular surface. Proper
allergic reactions can be clinically serious, however, their inci-
dence is deﬁnitely lower than the non-allergic alterations
caused by the chronic use of such drugs. The incidence of
proper allergic reactions is very different, depending on the
compound. Immediate allergic reactions are less frequent with
timolol than with other hypotensive drugs (Osborne et al.,
2005).
Some authors reported an incidence of 1.5% of allergic
reactions with latanoprost, when used as a second-line therapy
(Haverkamp et al., 2004).
Allergic reactions with brimonidine have been reported to
be between 4.2% and 25.7% (Manni et al., 2004); a lower
incidence has been reported with the use of the ﬁxed combi-
nation brimonidine-timolol (Manni et al., 2004; Motolko,
2008).
Severe periocular dermatitis, possibly associated with atyp-
ical likenoid reactions was reported to be associated with the
use of dorzolamide, even months after the beginning of the
therapy; the incidence of this type IV hypersensitivity reactions
are over all quite uncommon (Mullins et al., 2004; Delaney
et al., 2002).
4. Antiglaucoma drugs and ocular surface
Several epidemiological studies demonstrated that patients on
local IOP-lowering therapies complained about local discom-
fort (Jaenen et al., 2007; Pisella et al., 2002). The occurrence
of ocular surface disease (OSD) may be related to different
factors, such as age, sex, race, the presence of blepharitis and
the use of preserved eye drops (Brewitt and Sistani, 2001;
Baudouin and de Lunardo, 1998; Leung et al., 2008). Besides
the allergic reactions caused by the active compounds, preser-
vatives contained in the preparations may trigger an inﬂamma-
tory response. As with all patients affected by OSD, signs and
symptoms are not always related and many glaucomatous pa-
tients that complain of dry eye symptoms do not have any
measurable damage and vice-versa (Hay et al., 1998); however,
the discomfort related to antiglaucoma eyedrops use has been
reported as one of the most common causes of request for an
ophthalmological consultation. The symptoms may be related
either to the instillation or to the period between different ins-
tillations. Stinging and burning are common just after the
instillation of the eye-drops. Up to 25% of patients complainthe occurrence of side effects such as ‘‘pain’’ immediately after
the beginning of the therapy. The percentage rises up to 40% if
the symptom sought for is ‘‘burning’’ that might also cause
tearing. Other common symptoms are dry-eye sensation and
itching of the palpebral margin. Conjunctival hyperemia
related to topical prostaglandin application is usually consid-
ered disagreeable by the patient. It is caused by a local vasodi-
latation and its gravity is related to the compound and to
individual reactivity (Hollo`, 2007). Usually the degree of
hyperemia is apparently more severe than the symptoms (burn-
ing, stinging and itching).
Glaucoma patients are at high risk for developing ocular
surface disease because:
 Both glaucoma and OSD incidence increases with the age.
 A large portion of glaucomatous patients are treated with
preservative-containing pressure lowering eyedrops.
 The treatment is usually prolonged for years since glaucoma
is a chronic disease.
Besides OSD related discomfort and anatomical alterations,
several authors found a correlation between chronic topical
long-term therapy and a higher rate of subsequent ﬁltration
surgery failure (Leung et al., 2008; Broadway et al., 1994;
Yee, 2007). Immediately after surgery ﬁbroblasts tend to prolif-
erate, in order to repair the incised tissues, thus reducing the
ﬁltration of aqueous humor to the subconjunctival space. An
increase in inﬂammatory response leads to faster recruitment
of ﬁbroblasts that produce extracellular matrix. Long-term
therapy with preserved local hypotensive drugs leads to con-
junctival migration of macrophages and lymphocytes.
The conjunctival inﬂammatory reaction in glaucomatous
patients seems to be related both to the number of eye-drops
instillation and to the duration of the therapy. The toxic effect
of preservatives is likely to play a relevant role in the conjunc-
tival cicatricial response after surgery (Baudouin, 1996, 2008).5. Antiglaucoma drugs and preservatives
There is increasing evidence to demonstrate that a sizeable por-
tion of local side-effects may result from the preservatives
rather than from the active compounds. The most commonly
used preservative in anti-glaucoma medications is benzalkoni-
um chloride (BAK). BAK has been shown (Baudouin et al.,
1999) to induce signiﬁcant inﬂammatory and histopathological
changes in both the ocular surface and deeper ocular struc-
tures, and to induce apoptosis in conjunctival cells (Debbasch
et al., 2001).
As a quaternary ammonium, BAK, is most commonly asso-
ciated with irritant toxic reactions (8% in OVID and PubMED
based researches), whereas the organomercurials, such as thi-
merosal, and the alcohols, such as chlorobutanol, have the
highest associations with allergic responses (respectively,
19% of OVID and 14% of PubMED based researches and
20% of OVID and 11% of PubMED based researches). Such
reactions appear mainly like an irritant effect for alcohols,
whereas the organo-mercurials appear to truly interact with
the immune system as neoantigens (Hong and Bielory, 2009).
Non-quaternary ammonium preservatives seem to cause oxi-
dative stress to a signiﬁcantly lesser extent and to induce lower
cell death rate than BAK (Debbash et al., 2001).
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cells, conjunctival squamous metaplasia and apoptosis, disrup-
tion of the corneal epithelium barrier and damage of deep ocu-
lar tissues are far from being fully elucidated, but the
involvement of immunoinﬂammatory reactions was proposed.
The release of proinﬂammatory cytokines, apoptosis, oxidative
stress as well as direct interactions with the lipid layer of the
tear ﬁlm and cell membranes are well established (Baudouin
et al., 2010).
6. Antiglaucoma drugs: how to reduce the exposure to
preservatives?
Despite consistent data conﬁrming its potential toxic effects,
especially for a chronic use, BAK is still used as the main pre-
servative in eye drops. Considerable efforts have been made by
the pharmaceutical industry in the recent past, however, to de-
velop new antiglaucoma formulations that would bring about
efﬁcacy, safety and compliance. The most part of the antiglau-
coma drugs that have been commercialized during the last
years allows for a lower BAK exposure.
Different strategies can be considered in order to reduce the
amount of BAK administered when prescribing a therapeutic
antiglaucoma regimen.
6.1. Reducing the number of drops
As BAK toxicity is mainly dose-dependent, reducing the num-
ber of instillations can improve ocular tolerance (Baudouin
et al., 2010).
Prostaglandins and long-acting preparations of timolol are
given once rather than twice a day, thus reducing the amount
of BAK administered by 50% (Easty et al., 2006).
The same occurs with the use of ﬁxed-combined drugs prep-
arations. Fixed combinations of timolol and prostaglandins,
carbonic anhydrase inhibitors and brimonidine are currently
on the market and represent an important tool in order to opti-
mize glaucoma therapy. When two or more active molecules
are necessary to obtain an adequate IOP, ﬁxed-dose combina-
tion eye drops may offer advantages for patients, while
maintaining at least the same effect on IOP than separate
instillation of the same two products (European Glaucoma
Society, 2008c). As a general rule, compliance with any given
medical therapy in glaucoma, like other chronic diseases, is
better when regimens are simple rather than complex and
reducing the number of daily administrations can positively
affect patients’ quality of life (Olthoff et al., 2005). Moreover,Table 1 Summary of the antiglaucoma drugs currently available in
Category Molecule
b-Blockers Timolol 0.5–0.1%
Betaxolol 0.25%
Levobunol 0.5%
Carteolol 1–2%
Carbonic anhydrase inhibitors Dorzolamide 2%
a-Agonists Brimonidine 0.1–0.15
Prostaglandin analogues/prostamides Taﬂuprost 0.0015%
Travoprost 0.004%
Parasympathomimetics Pilocarpine
Fixed combinations: Timolol-Dorzolamidethe higher costs from more bottles seem to promote non-com-
pliance and reduce persistence (Soumerai et al., 2006). Besides
possible improved compliance, quality of life, costs saving and
also additional IOP lowering effect for some molecules (Higg-
inbothan, 2010), ﬁxed combinations allow for halving the daily
amount of BAK and related side-effects. Although no deﬁni-
tive data exist, at least some of the currently available ﬁxed
combination have shown a better safety proﬁle and tolerability
when compared with the same molecules used separately
(Sleath et al., 2006; Hommer, 2007).
6.2. Using of preserved formulation not containing BAK
Overall, BAK has an apparently good safety/efﬁcacy proﬁle; it
is weakly allergenic and has a high rate of antimicrobial prop-
erties. Worth to remember is that the Pharmacopoeia recom-
mends that eye drops must contain an antimicrobial agent
(preservative) to avoid or limit microbial proliferation after
opening of the bottle, which could induce a risk of potentially
severe eye infection as well as alteration of the formulation
(Baudouin et al., 2010). Conversely, deﬁnitive data suggest that
avoiding its toxicity should be of beneﬁt for a large portion of
glaucomatous patients. Extensive research has been conducted
to discover and develop less toxic preservatives than quaternary
ammoniums. However, since preservatives must be potent anti-
microbial agents while not being cytotoxic, only few agents
have been proposed and are commercially available (Baudouin
et al., 2010). Purite is a stabilized oxychloro complex acting as
an oxidative preservative that is converted into natural tear
components when exposed to light (Kim et al., 2007). This mol-
ecule has shown a wide spectrum of antimicrobial activity and a
very low-level toxicity in mammalian cells (Grant et al., 1996).
When Purite was used in formulations of brimonidine 0.15%
it resulted in signiﬁcantly better tolerance as compared to BAK
containing brimonidine 0.2%, especially in irritated eyes (Mun-
dorf et al., 2003). Sofzia is a preservative system composed of
boric acid, propylene glycol, sorbitol and zinc chloride that
causes oxidative damage and consequent death to organisms
that lack the enzymes cytochrome oxidase and catalase, such
as most species of bacteria; human cells posses these enzymes
and are thus not similarly harmed (Ammar et al., 2010). Henry
and coworkers found signiﬁcant improvement of ocular surface
symptoms and hyperemia and similar IOP lowering effect when
patients treated with latanoprost or bimatoprost were switched
to Sofzia-preserved travoprost (Henry et al., 2008). Polyquad
(polyquaternium-1) belongs to the family of plycationic poly-
mers named polyquaternium and is commonly used as a multi-either preservative- and/or BAK-free formulations.
Pharmaceutical form
Single dose container/ABAK, COMOD system
Single dose container
Single dose container
Single dose container/ABAK system
Single dose container
% BAK-free solution (preservative: Purite)
Single dose container
BAK-free solution (preservative: Sofzia, Polyquad)
Single dose container
Single dose container
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drops as an alternative to BAK (Lipener, 2009). Labbe et al
showed higher toxic effects in the ocular surface of rats treated
with BAK than those exposed to Polyquad (Labbe et al., 2006).
Similarly, Ammar et al found that the substitution of BAKwith
Polyquad resulted in signiﬁcantly higher percentages of human
live conjunctival and corneal cells (Ammar et al., 2011).
6.3. Preservative-free formulations
The only way to completely eliminate BAK/preservative-
related side effects is obviously to remove them from the
eyedrops. However, due to the above mentioned Pharmaco-
poeia recommendations, this approach raises industrial and
regulatory concerns since non-preserved eyedrops in multidose
bottles could enhance the risk of contamination.
To address this concern, single-dose units are the most fre-
quently used preservative-free formulations. Different beta-
blockers, pilocarpine and more recently a ﬁxed combination
of timolol and dorzolamide as well as the prostaglandin ana-
logue taﬂuprost have been commercialized as single-dose units
(Hommer and Kimmich, 2011). Less cost-effectiveness and dif-
ﬁcult handling have been pointed out regarding these formula-
tions and their use by older patients and with inappropriate
ﬁnger manipulation could be associated with an increased risk
of contamination. However, Kim et al reported that even in
the worst conditions of poor administering technique of unpre-
served artiﬁcial tears, only 2% of 242 reclosable containers had
bacterial contamination after three times or more instillation
within 10 h (Kim et al., 2008). Conversely, Tasli and Cosar
found a 35% rate of contamination after 15 days in a multi-
ple-use setting of bottles preserved with BAK (Tasli and
Cosar, 2001).
Newer multidose formulations have been developed: either
by allowing for preservative ﬁltration and adsorption on a por-
ous membrane or by using a valve system that hinders penetra-
tion of bacteria into the bottle (Baudouin et al., 2010).
Different beta-blockers have been available with the ABAK
or COMOD systems for a number of years. Different clinical
studies conﬁrmed substantial improvement of the patient’s
ocular surface after starting the use of BAK-free drops
(Baudouin et al., 2010).7. Conclusions
When selecting medical treatment for glaucoma it is impor-
tant to understand not only the primary aim of the therapy
but also contraindications and side effects of each medication
for every single patient. Besides efﬁcacy, the choice of therapy
must take into account tolerability, related quality of life and
adherence to treatment (European Glaucoma Society, 2008c).
Preservatives contained within topical eye drop preparations
may cause inﬂammatory conjunctival side effects and toxicity
of the ocular surface (Blondin et al., 2003; Baratz et al.,
2006).
The use of preservative-free preparations/delivery systems,
the reduction of the number of instillation or the choice of for-
mulations containing preservatives less toxic than BAK should
be considered to lessen such problems. This should lead to bet-
ter tolerability and possibly higher adherence to the treatment
and improvement of patients’ quality of life.Within the past 5–7 years, a number of ocular hypotensive
drugs have been re-formulated in preservative-free versions
and some have changed preservatives, while maintaining
equally effective IOP-lowering effects. Preservative free formu-
lations of timolol, betaxolol, dorzolamide, a ﬁxed combination
of timolol-dorzolamide and taﬂuprost are actually available;
formulations of travoprost and brimonidine containing preser-
vatives less toxic than BAK are also available (see Table 1).
As a general rule, preservative-free eyedrops could be partic-
ularly beneﬁcial to patients with the following characteristics
(Baudouin, 2008; Bagnis et al., 2011; European Glaucoma
Society, 2008a,b,c):
 pre-existing or concomitant dry eye/ocular surface disease
 those receiving a multidrug topical treatment
 those whose treatments are expected to last over several
years/decades
 those who are about to undergo glaucoma surgery.
Patients showing one or more of these features are likely to
beneﬁt from BAK-free formulations as well as from minimiz-
ing the exposure to BAK by the use of ﬁxed combined
preparations.References
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